Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy (LAMBCHOP)
LAMBCHOP-Lubiprostone Activity Among the MicroBiota of the Colon in HIV in Opposing Permeability: Pilot Study of Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 T-cell Recovery on Antiretroviral Therapy
Sponsor: Ruth M. Rothstein CORE Center
Listed as NCT01839734, this PHASE2 trial focuses on HIV and remains completed. Sponsored by Ruth M. Rothstein CORE Center, it has been updated 8 times since 2013, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jan 2021 — Sep 2023 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 3 earlier versions
-
May 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ruth M. Rothstein CORE Center
For direct contact, visit the study record on ClinicalTrials.gov .